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the Homeobox gene, HOXB13, 
Regulates a Mitotic protein-Kinase 
Interaction Network in Metastatic 
prostate Cancers
Jiqiang Yao1, Yunyun Chen1, Duy t. Nguyen2, Zachary J. thompson1, Alexey M. eroshkin3, 
Niveditha Nerlakanti4, Ami K. patel4, Neha Agarwal4, Jamie K. teer1, Jasreman Dhillon5, 
Domenico Coppola5, Jingsong Zhang6, Ranjan perera7, Youngchul Kim1 & Kiran Mahajan2
HOXB13, a homeodomain transcription factor, is linked to recurrence following radical prostatectomy. 
While HOXB13 regulates Androgen Receptor (AR) functions in a context dependent manner, its 
critical effectors in prostate cancer (PC) metastasis remain largely unknown. To identify HOXB13 
transcriptional targets in metastatic PCs, we performed integrative bioinformatics analysis of 
differentially expressed genes (DEGs) in the proximity of the human prostate tumor-specific AR binding 
sites. Unsupervised Principal Component Analysis (PCA) led to a focused core HOXB13 target gene-
set referred to as HOTPAM9 (HoXB13 targets separating primary And Metastatic PCs). HOTPAM9 
comprised 7 mitotic kinase genes overexpressed in metastatic PCs, TRPM8, and the heat shock 
protein HSPB8, whose levels were significantly lower in metastatic PCs compared to the primary 
disease. The expression of a two-gene set, CIT and HSPB8 with an overall balanced accuracy of 98.8% 
and a threshold value of 0.2347, was sufficient to classify metastasis. HSPB8 mRNA expression was 
significantly increased following HOXB13 depletion in multiple metastatic CRpC models. Increased 
expression of HSPB8 by the microtubule inhibitor Colchicine or by exogenous means suppressed 
migration of mCRPC cells. Collectively, our results indicate that HOXB13 promotes metastasis of PCs by 
coordinated regulation of mitotic kinases and blockade of a putative tumor suppressor gene.
Prostate cancer (PC) is a commonly diagnosed cancer among American men1. The prognosis of metastatic 
castration-resistant prostate cancer (mCRPC) is particularly bleak as the disease progresses after an initial 
response to androgen deprivation therapies (ADT) with the 5-year survival at ~28%2–5. While multiple studies 
have highlighted the role of tyrosine kinases, expression of the variant AR-V7 or AR-interacting epigenetic mod-
ifiers in mCRPC survival, recent studies indicate the importance of tissue-specific and developmentally regulated 
transcription factors in the disease progression2,6. Importantly, shared oncogenic transcription factors and epige-
netic regulators can reprogram normal cells of distinct epithelial lineage to converge towards cancer cell lineages 
with similar molecular features underscoring the importance of these drivers in establishing the tumor landscape 
and promoting metastasis7–10.
The HOX family is an evolutionarily conserved group of gene clusters that code for transcription factors char-
acterized by the presence of homeodomains11. Among these, HOXB13 has emerged as a critical mediator of 
CRPC growth through multiple mechanisms, including its ability to modulate the genomic recruitment of the 
constitutively active AR splice variant AR-V712–16. Further, a germ line mutation in HOXB13 (G84E) has been 
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identified which is not only associated with an increased risk of familial and hereditary PC, but male carriers also 
appear more likely to develop the aggressive form of the disease17,18.
During mouse embryonic development, HOXB13 is expressed in the caudal portion of the tail bud, spinal 
cord and urogenital sinus19. It is essential for the differentiation of the secretory cells in the ventral lobes of 
the prostate18. Subsequently, HOXB13 expression is not completely switched off but is maintained at low levels 
in adult prostatic tissues19. Even at the earliest stages of mouse embryogenesis, a concurrent expression of AR 
and HOXB13 is observed; however, HOXB13 expression is not dictated by androgen18–22. A context depend-
ent role for HOXB13 has been noted in androgen-dependent versus hormone-refractory prostate cancers20,22,23. 
Mechanistically it has been proposed that HOXB13 can function as a tether, collaborator or negative regulator 
of the Androgen receptor due to its ability to modulate the expression Androgen-regulated genes11,24. In prostate 
cancer cells, the BET bromodomain protein family member, BRD4, epigenetically regulates HOXB13 expres-
sion16. Moreover, integrative bioinformatics analysis identified an AR independent BRD4-HOXB13 dependent 
transcriptome as a proliferative gene network involved in cell cycle progression, nucleotide metabolism, and 
chromatin assembly5. Consistently, genetic depletion of HOXB13 or pharmacological blockade significantly 
impacts the ability of metastatic CRPC cells to from xenograft tumors in castrated immunocompromised mice16. 
Combined, these results underscore the dependency of mCRPCs on HOXB13 regulatory networks particularly 
when androgen-dependent AR signaling is impacted and is consistent with its requirement in metastasis22,23.
Increased HOXB13 and AR expression is a hallmark of advanced primary and bone metastatic PCs25,26. 
Notably, while ~9700 tumor-specific AR binding sites (T-ARBS) were reported to be enriched for the HOXB13/
FOXA1 motifs; which of the putative AR or HOXB13 target genes are critical for tumor growth or metastasis is 
not well-investigated24. In this study, to identify the mechanism by which HOXB13 promotes metastasis, we per-
formed integrative bioinformatics analysis to uncover genes that are significantly impacted as a result of HOXB13 
depletion in a metastatic PC model cell line and are also differentially expressed in human prostate tumors. This 
integrative analysis approach revealed a previously unknown network of mitotic kinases and a putative tumor 
suppressor gene whose expression is significantly modulated between primary and metastatic PCs. Collectively, 
our results indicate that metastasis of prostate cancers is a highly orchestrated event regulated by the transcrip-
tional of activity of the homeobox gene HOXB13.
Results
A core HOXB13 target gene set, HOTPAM9, can stratify primary from metastatic PCs. HOXB13 
is expressed in androgen-dependent LNCaP and VCaP cell lines as well as androgen-independent mCRPC cell 
lines, C4-2B and 22Rv127. We chose C4-2B for further evaluation as this cell line expresses HOXB13 and AR, 
shows significant resistance to the anti-androgen Enzalutamide, and metastasizes in castrated immunocompro-
mised male mice2,16. To identify HOXB13 transcriptional targets in high-risk metastatic human PCs, we per-
formed integrative bioinformatics analysis of 536 differentially expressed genes (DEGs) in the proximity of the 
tumor-specific AR binding sites (T-ARBS) enriched for HOXB13/FOXA1 binding motifs24 (Supplementary 
Fig. 1a) with the 2677 DEGs that were found to be significantly affected as a result of HOXB13 reduction in 
the metastatic CRPC cell line, C4-2B/pHOXB13KO (Fig. 1a)16. Integrative bioinformatics analysis yielded 87 
HOXB13 specific target genes (HOXTAR87) (Fig. 1a,b) in proximity of the T-ARBS sites. We observed that fol-
lowing HOXB13 reduction, genes which are highly expressed in C4-2B/pHOXB13KO were downregulated in 
human prostate tumors while those with reduced expression in C4-2B/pHOXB13KO were upregulated in human 
prostate tumors compared to normal prostates (Fig. 1b).
To further ascertain the clinical significance of HOXTAR87, we analyzed their expression in the microarray 
data obtained from 194 localized and 29 metastatic tumors from the Moffitt Cancer Center Total Cancer Care 
(TCC) dataset (Supporting Data Table 1). Unsupervised Principle Component Analysis (PCA) was performed 
on Moffitt TCC gene expression data employing the HOXTAR87 genes. We observed separation between the 
primary and metastatic cancers in the second Principal Component. Subsequently, to identify a minimal gene set 
driving this separation, we selected genes with the most extreme loadings and identified a 9-gene set that maxi-
mized the separation of primary and metastatic cancers when reapplied in the first Principle Component. Heat 
maps were generated for this 9-gene subset (Fig. 1c; Supporting Data Table 2). The 9 gene-set could effectively 
distinguish primary organ confined from metastatic PCs by first component of PCA at 56.7% (Fig. 1d). This 9 
core HOXB13 target gene set is referred to as the HOTPAM9 (HOXB13 Target genes separating Primary and 
Metastatic PCs).
The HOTPAM9 core gene set was then independently validated for its ability to separate primary from met-
astatic tumors in the publicly available MSKCC data set- 179 samples (29 normal, 131 primaries and 19 metas-
tasis)28 (Fig. 1e,f; Supporting Data Table 3). HOTPAM9 gene set was also effective at separating primary tumors 
from adjacent normal and primary from metastatic cancers (compare Fig. 1d,f; Supporting Data Table 4).
To further ascertain the significance of HOXB13 target genes in additional data sets, we performed 
meta-analysis of gene expression data from genetically engineered mouse models (NKX3.1CreERT2/+/PTENflox (NP 
mice) and the NPp53flox (NPp53 mice)3. These mice specifically lose prostate-specific expression of PTEN and 
tumor suppressor p53 in the epithelial compartment following tamoxifen treatment and develop CRPCs follow-
ing castration with molecular features reminiscent of metastatic human CRPCs3. Gene Set Enrichment Analysis 
(GSEA) (Fig. 1g–i) revealed a positive enrichment for the HOXB13 target genes (HOXTAR87) specifically in 
tumors derived from NPp53 CRPC compared to NKX3.1CreERT2/+ mice (N) (NES = 1.35, p = 0.045) (Fig. 1; com-
pare g to h). A significant enrichment of HOXTAR81 was not observed in NP vs N mice (NES = 1.29, p = 0.089) 
(Fig. 1g), NP CRPC vs NP (NES = −0.92, p = 0.610), NPp53 CRPC vs Np53 (NES = −0.79, p = 0.88), NPp53 
CRPC vs NP CRPC (NES = 1.25, p = 0.096 (Supplementary Figs 2a–c). In contrast, the NPp53 CRPC mice treated 
with Abiraterone (ABR), a subset referred as exceptional non-responders due to their propensity to develop 
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accelerated tumor phenotypes and metastasis revealed a significant enrichment (NES = 1.37, p = 0.023) (Fig. 1i), 
suggesting a tendency for these HOXTAR81 genes to regulate a metastatic CRPC program. Together, these results 
suggest that upregulation of the HOXB13 target gene expression correlates with severity of disease progression 
and anti-androgen resistance.
HOTPAM9 genes are transcriptional targets of HOXB13 in PC. Violin plots revealed that a majority 
(6/9) of the HOTPAM9 metastasis signature were overexpressed in metastatic tumors compared to the primary 
tumors in the Moffitt TCC data set (Fig. 2a; Supporting Data Table 5) and MSKCC (GSE21034) validation data 
set (Fig. 2b; Supporting Data Table 6) and GSE6919 (Supplementary Fig. 2d; Supporting Data Tables 7–10). In 
contrast, expression of the putative tumor suppressor gene, HSPB829, was found to be consistently downregulated 
in multiple clinical data sets (Fig. 2a,b, Supplementary Fig. 2d; Supplementary Data Tables 5, 6 and 10). Search 
Tool for the Retrieval of Interacting Genes (STRING) analysis revealed that a majority of the HOTPAM9 genes 
are serine/threonine kinases that cross-talk through protein-protein interactions (PPI enrichment p-value: 1.47e-
13) to ensure high fidelity chromosome separation during mitosis. These kinases monitor centrosome separation, 
bipolar spindle assembly, chromosome alignment and cytokinesis (Fig. 2c,d). Pathway analysis revealed a subset 
of the HOTPAM9 genes (AURKA, BUB1, CIT, NUF2, NEK2, and NCAPG) regulate key phases of cell division 
(Fig. 2d). Distinct from the HOTPAM9 kinases and not a part of the network is the Transient Receptor Potential 
cation channel subfamily member M8, TRPM8, which regulates PC cell migration, and hence suggests a role in 
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Figure 1. HOXB13 target genes stratify primary from metastatic prostate tumors. (a) Venn Diagram of overlaps 
between DEGS (536 genes) in proximity of the Tumor specific AR binding sites (T-ARBS sites) and DEGS 
obtained following HOXB13 reduction (2677genes) in HOXB13pKO (n = 2 biological replicates) compared to 
C4-2B-Parental. (b) Heat map comparing expression of the 87 HOXB13 target genes obtained by integrative 
analysis in (a). Expression values were standardized to mean = 0 and standard deviation = 1 and hierarchically 
clustered. (c) Heat map of microarray analysis showing expression of 9 selected genes (HOTPAM9) in total 
n = 223 (194 primary and 29 metastatic tumors) in the Moffitt Cancer Center TCC data set. Red bars indicate 
metastatic tumors. (d) Principle Component Analysis (PCA) modeling HOXB13 target genes in 223 PC 
samples. (e) Heat map of prostate tumor microarray analysis showing expression of HOTPAM9 genes in the 
MSKCC data set (GSE21034). Red bars indicate metastatic tumors. (f) PCA analysis modeling HOTPAM9 in 
179 samples (29 normal, 131 prostate adenocarcinomas and 19 metastasis). (g-i) Gene set enrichment analysis 
of HOXB13 target genes in castrated NKX3.1haplo(N), NKX3.1haplo PTENcnull (NP), and NKX3.1haplo PTENcnull 
p53cnull (NPp53) genetically engineered mouse models of prostate adenocarcinoma.
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To confirm that the HOTPAM9 genes are regulated in a HOXB13-dependent manner PC cell lines27 C4-2B, 
LNCaP, VCaP and PC3 were transfected with control or HOXB13 silencing RNAs either singly or pooled (siR-
NAs). After 48 hours, the relative expression of HOTPAM9, HOXB13 and c-MYC was examined by quantitative 
Reverse Transcriptase PCR (qRT-PCR) with gene-specific primers. We observed that expression of a majority 
of the HOTPAM9 kinase expression was significantly impacted when HOXB13 expression was silenced with 

















































































































Figure 2. HOTPAM9 comprises a mitotic protein-protein interaction network. (a) Violin plots displaying 
HOTPAM9 gene expression differences in the primary versus metastatic cancers in the Moffitt Cancer Center 
TCC data set. (b) Violin plot of HOTPAM9 genes in MSKCC validation data set. (c) STRING analysis of 
the HOTPAM9 genes indicating Protein-Protein Interaction network (PPI). PPI enrichment p-value, 1.47 
e-13. (d) Gene Ontology (GO) analysis revealed 9 significantly enriched gene sets impacted by HOXB13 
depletion. LNCaP (e) and C4-2B (f) cells were transfected with control or HOXB13 siRNA. Total RNA was 
isolated, followed by qRT-PCR with HOXB13, c-MYC and HOTPAM9 primers. Data are represented as 
mean ± SEM and normalized to actin. n = 2 biological replicates, triplicate samples in each biological replicate. 
****p < 0.0001, ns: not significant.
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in charcoal stripped media, but not in the small cell carcinoma cell line PC3 (Fig. 2e,f, Supplementary Fig. 2e). 
In contrast, the expression of HSPB8 gene was significantly upregulated in both AR positive cell lines (LNCaP, 
C4-2B, and VCaP) as well as an AR negative cell line (PC3) (Fig. 2e,f, Supplementary Fig. 2e). c-MYC was used as 
a negative control and its expression remains unchanged following HOXB13 silencing in AR positive cell lines but 
was upregulated in the PC3 (Fig. 2e,f; Supplementary Fig. 3b). Silencing of HOXB13 also impacted AR/AR-V7, 
PSA and NKX3.1 in VCaP and C4-2B but not TMPRSS2 in VCaP (Supplementary Fig. 3a,b). NKX3.1 is a previ-
ously characterized HOXB13/AR target gene and was down regulated in both models (Supplementary Fig. 3a,b)11.
To determine whether HOTPAM kinases promote mCRPC proliferation, we transfected C4-2B cells with 
individual siRNAs for HOXB13 as well as 8 HOTPAM kinase genes respectively (Fig. 3a,b) and examined impact 
on PC cell proliferation (Fig. 3c). Silencing either HOXB13 or HOTPAM9 kinase gene expression (NCAPG, 
BUB1, NUF2, CIT, MKI67 and AURKA) significantly impacted C4-2B cell proliferation (Fig. 3c,d). These results 
reveal a novel network hijacked by HOXB13 to promote mCRPC growth and uncovers actionable targets in AR 
positive luminal epithelial subtype of PCs as these HOTPAM kinases are all potentially druggable entities.
HOXB13 recruitment to HOTPAM9 metastasis signature genes is tumor-specific. Distinct 
T-ARBS and HOXB13 peaks were found within a proximity of a subset of the HOTPAM9 metastasis signa-
ture genes (Supplementary Fig. 1b). ChIP sequencing data (GSE56288) revealed recruitment of AR to the 
vicinity of the HOTPAM9 genomic regions in the tumor tissues but not in normal prostates (Supplementary 
Fig. 1b). We synthesized primers corresponding to the AR/HOXB13 peak enrichment sites in the Chromatin 
Immunoprecipitation-sequencing (ChIP-sequencing-GSE56288) data of human prostate tumors24. Importantly, 
these sites were also enriched for HOXB13 binding motifs in HOXB13 ChIP sequencing data. Chromatin immu-
noprecipitation with HOXB13 antibody revealed binding at NCAPG, TRPM8, NUF2, BUB1, and HSPB8 (Fig. 4a–f) 
loci suggesting recruitment of HOXB13 to these target genes. We have previously identified AURKB as a HOXB13 
transcriptional target in prostate cancer.
Clinical correlations of HOTPAM9 gene expression with survival. Subsequently we examined 
the association of HOXB13 gene expression with multiple clinical parameters in the Moffitt TCC (Table 1) and 
MSKCC data sets respectively (Supplementary Table 1). Kaplan-Meier survival curves were generated based 
on categorized high and low gene expression levels for the HOXB13 genes with Moffitt and MSKCC data sets 
(Supplementary Fig. 4). Notably, the overall log rank test is significant for HOXB13 when considering overall 
survival for Moffitt TCC data set and recurrence free survival (RFS) for MSKCC data set. Further, in the Moffitt 
data set, based on log-rank test and univariate Cox proportional hazard regression analysis, only age was found 
to be significantly associated with overall survival time for patients with primary PC (Supplementary Fig. 5). In 
the MSKCC data set, Gleason score, clinical tumor stage, margin status and PSA at diagnosis were significantly 
associated with patients’ recurrence-free survival time (all log-rank test p-value < 0.05) (Supplementary Fig. 6). 
Kaplan-Meier survival probability curves were generated based on Principle Component 1(PC1) and 2 (PC2) 
with Moffitt and MSKCC data sets (Fig. 5). Notably, the overall log rank test is significant when considering over-
all survival for PC1 and PC2 in Moffitt TCC data set and recurrence free survival (RFS) for the MSKCC data set.
Kaplan-Meier overall survival analysis for the HOTPAM9 genes in the Moffitt TCC data set revealed low 
NEK2 downregulation (↓;), BUB1 (↓), and NCAPG (↓) were significantly associated with better overall survival 
times (Log-rank test p < 0.05). In contrast to these genes, high HSPB8 (↑; over-expression) was observed to be 
significant (p = 0.0001) (Supplementary Fig. 7). In the MSKCC data set low NEK2 (↓), BUB1 (↓), and NCAPG 
(↓) were significantly associated with better RFS (Log-rank test p < 0.0001) while high HSPB8 (↑) was significant 
(p = 0.0001) (Supplementary Fig. 8). Gleason score, clinical tumor stage, lymph node involvement, margin status, 
NEK2, BUB1 and NCAPG in 9-genes cluster were significant by univariate Cox proportional hazard regression 
analysis. For multivariable analysis, Gleason score, lymph node involvement and BUB1 in 9-genes cluster were 
significant (Hazard ratio for BUB1 = 3.94 and 95% confidence interval = [1.58, 9.86]) (Table 2).
Identification of a two- gene subset, CIT/STK21 and HSPB8, that facilitates stratification of 
metastatic pCs. As a further refinement of the core HOTPAM9 gene set, we built a multi-gene expression 
model to stratify primary from metastatic PC. The final output of the model is a probability score of developing 
metastases of PC. Each statistical model was trained on the basis of 150 patients in the MSKCC data set and came 
out with an optimal threshold value to classify patients with primary versus metastatic cancer. Receive operating 
characteristic (ROC) analysis showed an overall balanced accuracy of 98.8% and a significantly high area under 
the curve of 0.981 and a threshold value of 0.2347 in its evaluation of the MSKCC data set (Fig. 5b). The optimal 
model and threshold were then tested on Moffitt TCC data set to assess stratification performance of the model. 
Applying this model to the Moffitt TCC data set resulted in an overall balanced accuracy of 90.8% and a signifi-
cantly high area under the curve (AUC) of 0.994 (p < 0.01), as compared to AUC of 0.5 for a random classification 
(Fig. 5c). Notably, our model revealed that two selective genes, the cell division gene CIT/STK21 and the putative 
tumor suppressor gene HSPB8 were sufficient to predict metastasis.
HOXB13-CIT kinase axis predicts poor prognosis of metastatic prostate cancers. As reduction 
in both CIT kinase and HOXB13 negatively impacted mCRPC proliferation, we examined whether it is a direct 
transcriptional target of HOXB13. Analysis of ChIP sequencing data (GSE56288) for the recruitment of HOXB13 
and AR to the vicinity of the CIT/STK21 revealed overlapping peaks, consistent with our original selection for 
tumor-specific ARBS. Directed ChIP-quantitative PCR revealed binding of HOXB13 in the proximity of the CIT 
promoter but not at a control site, IGX1A (Fig. 6a,b). Conversely, high expression of CIT kinase in metastatic 
PCs is associated with poor outcomes in both Moffitt and MSKCC data sets (Fig. 6c,d). Collectively, our results 
indicate CIT kinase as a potential biomarker and therapeutic vulnerability in metastatic PCs.
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HSPB8 mRNA levels are inversely correlated with HOXB13 and AR expression in metastatic PCs. 
HOXB13 and AR are co-expressed in metastasis at distant sites and positively correlate in multiple clinical data 
sets (Fig. 7a–c; Supplementary Fig. 9). Conversely, we observed that HSPB8 mRNA levels showed inverse cor-
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Figure 3. Effect of HOXB13 and HOTPAM9 gene silencing on mCRPC proliferation. (a) C4-2B cells were 
transfected with control or HOXB13 siRNAs (#1 is individual and #2 is pooled). Whole cell lysates were 
immunoblotted with anti-HOXB13 or anti-AR antibodies. Actin is a normalization control. (b–d) C4-2B cells 
were transfected with control or HOXB13 or HOTPAM9 siRNAs. (b) Total RNA was isolated, followed by qRT-
PCR with primers corresponding to the transfecting siRNA. Actin is a normalization control. (c) Cells were 
harvested, stained with Trypan blue, and counted using a hemocytometer 96 h post-transfection. siRNAs #1 data 
represent n = 2 biological replicates, duplicate samples in each biological replicate. (d) Cells were stained with the 
Live-Dead staining dye 96 h post-transfection and captured using the EVOS-M5000 microscope. Scale bar 300 µm. 
Data are represented as mean ± SEM in (b-c). ****p < 0.0001, ***p < 0.0005, *p < 0.05, ns: not significant.
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data set, GSE21034, GSE101607, GSE6752, GSE67980 and SU2C/PCF datasets (Fig. 7a–i; Supplementary Fig. 9). 
Even when comparing primary to metastasis within the Moffitt TCC data set as well as in the GSE6919 dataset 
(196 primary and 75 metastatic samples), HSPB8 mRNA levels were significantly lower, (log2 fold change −1.952; 
p value = 6.76E-15) (Fig. 7f; Supplementary Fig. 2d, Supporting Data Table 10). In contrast, HSPB8 mRNA 
expression was significantly upregulated in multiple metastasis cell line models following HOXB13 reduction 
(Supplementary Fig. 2e). Both castration-sensitive and castration-resistant metastatic PCs showed similar levels 
of expression of AR, HOXB13 and the HOTPAM genes (Supplementary Fig. 10).
Effect of HSPB8 overexpression on PC cell migration. Immunoblot analysis revealed that HOXB13 
is expressed in AR positive PC cell lines of luminal epithelial origin as well as in AR negative PC3, a cancer of 
small cell origin (Fig. 8a). We observed that HSPB8 protein is expressed at very low levels in multiple PC cell lines 
tested (Fig. 8a,b). To determine whether HOXB13 mediated HSPB8 downregulation is a mechanism to facilitate 
PC cell migration, C4-2B were transfected with GFP vector or GFP-HSPB8 (Fig. 8b). Further, the effect of HSPB8 
overexpression was also examined in AR-V7 positive 22Rv1 and AR negative PC3 cells (Fig. 8c). Overexpression 
of HSPB8 significantly reduced the migration of highly aggressive PC cells (Fig. 8d,e).
The tumor suppressor gene HSPB8 is a target of HOXB13. To confirm the regulation of 
the HOTPAM9 genes by HOXB13 and the effect of anti-androgens, we analyzed their expression in 
androgen-responsive (LNCaP) and bone metastatic castration-resistant model cell line (C4-2B) treated with 
vehicle and Enzalutamide. A majority of the HOTPAM9 mRNA levels were expressed at higher levels in C4-2B 
treated with Enzalutamide compared to LNCaP except for TRPM8 whose levels decreased, indicating an andro-
gen regulated gene. In contrast, HSPB8 levels increased significantly in response to Enzalutamide (Fig. 9a). To 
















































































































Figure 4. Recruitment of HOXB13 to a subset of HOTPAM9 target genes. (a–g) Directed ChIP-quantitative 
PCR of C4-2B chromatin extracts for the recruitment of HOXB13 to HOTPAM9 genomic regions including 
NCAPG, HSPB8, TRPM8, NUF2, BUB1 binding sites. IGX1A is control site. AURKB is positive control gene for 
HOXB13 recruitment. Data are represented as mean ± SEM. ****p < 0.0001, ***p < 0.0005, **p < 0.01.
8Scientific RepoRts |          (2019) 9:9715  | https://doi.org/10.1038/s41598-019-46064-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
ascertain HOXB13 and/or AR dependency of the HOTPAM9 gene expression, C4-2B cells were transfected with 
Control, HOXB13 or AR silencing RNAs, and the expression of HOTPAM9 genes were analyzed in the vehi-
cle and Enzalutamide treated cells (Fig. 9b,c). In HOXB13 siRNA transfected C4-2B cells, HSPB8 expression 
was significantly increased while AR silencing had a marginal effect (Fig. 9b). However, in cells treated with 
Enzalutamide, depletion of either HOXB13 or AR mRNA led to a significant upregulation of HSPB8 gene expres-
sion compared to Control (Fig. 9b,c). ChIP-sequencing analysis revealed two HOXB13 binding sites upstream of 
HSPB8  (Fig. 9d,e).
Colchicine, a tubulin inhibitor, has been reported to induce expression of HSPB8 as well as inhibit PC 
growth32,33. While we did not detect accumulation of HSPB8 protein levels in response to Enzalutamide in C4-2B, 
we observed that treatment with Colchicine decreased HOXB13 and also induced HSPB8 mRNA and protein 
expression (Fig. 9f–j). Moreover, consistent with our overexpression studies, treatment of PC cells with Colchicine 
but not Enzalutamide impaired migration of PC cells (Fig. 9k,l).
Discussion
Our present study suggests that HOXB13, a critical regulator of metastatic PC growth16,34,35, directs a robust 
pro-proliferative androgen-independent transcriptional program by increasing the expression of a subset of 
mitotic kinases (Fig. 10: Model). Indeed, Wang et. al., reported upregulation of mitotic cell cycle genes in PC 
cells growing under long term conditions of androgen deprivation as well as in clinical androgen independent 
PC samples36. Increased expression of cell cycle kinases such as AURKA, BUB1, BUB3 and PIM1 is frequently 
observed in metastatic PCs5,8,10,37,38. Further, extensive molecular profiling comparing primary and metastatic 
human PCs has yielded significant insights into the different subsets as well as actionable targets of prognostic 
significance in metastatic PCs4,6,8,10,37–41. In agreement with these studies, gene ontology (GO) studies revealed 
that the top ten pathways affected as a result of HOXB13 knockdown were associated with the cell cycle, including 
DNA replication, G1/S phase, and the metaphase checkpoint. Moreover, that complete deletion of HOXB13 in 
LNCaP, VCaP and C4-2B PC models is lethal is consistent with its essential role in directing the expression and 
function of mitotic checkpoint kinases. We did not observe a significant enrichment of HOXB13 target gene sig-
nature in NPCRPC vs NP or NPp53, suggesting some degree of mutual exclusivity of HOXTAR genes with PTEN 
and p53 deletion. As PTEN and TP53 (as well as RB1) aberrations are a frequent genetic aberration in advanced/ 
metastatic prostate cancers4,10,38; HOXB13 in metastasis/CRPCs with no aberrations in TP53/ PTEN, could define 
a new subset.
Alterations in expression of a subset of these HOTPAM9 mitotic kinases have previously been reported to 
potentiate tumorigenesis through increased genome instability and aneuploidy42–46. For example, overexpres-
sion of NEK2, encoding a serine/threonine kinase associated with centrosome duplication and spindle assembly 
checkpoint, has been found in various malignancies and linked to poor prognosis42,47. While the 2 -geneset is 
sufficient for metastasis prediction, the HOTPAM9 gene set is more informative into kinases that are specifically 
overexpressed in metastatic populations that likely facilitate rapid proliferation and clonal expansion than their 
Variable
Metastatic Primary
P-valueN = 29 N = 194
Age at diagnosis (years) <64 Years 8 (27.6%) 130 (67.0%) 0.014
> = 64 Year 13 (44.8%) 63 (32.5%)
missing 8 (27.6%) 1 (0.5%)
Gleason Score 5–6 — 64 (33.0%)
7 — 125 (64.4%)
8–10 — 3 (1.5%)
Missing — 2 (1.0%)
Clinical Tumor Stage T1A,T1C — 152 (78.4%)
T2,T2A,T2B,T2C — 37 (19.1%)
Missing — 5 (2.6%)
Lymph node involvement 0.023
N1 1 (3.4%) 1 (0.5%)
N0 1 (3.4%) 172 (88.6%)
Missing 27 (93.1%) 21 (10.8%)
Margin Status Negative — 144 (74.2%)
Positive — 49 (25.3%)
Missing — 1 (0.52%)
Hormone(second course) <0.001
No 0 (0%) 186 (96.4%)
Yes 5 (17.2%) 7 (3.6%)
Missing 24 (82.8%) 1 (0.5%)
Table 1. Association between baseline clinical characteristics with patients’ disease type for Moffitt TCC data. 
*P-values for categorical variables calculated using the Fisher’s Exact method.
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primary counterparts. Indeed, the overexpression of mitotic kinases is consistent with a role for centrosomal 
amplification and mitotic propensity in driving intratumoral heterogeneity, tumor progression and metastasis48.
CIT/STK21 kinase is a direct transcriptional target of HOXB13 and an increase in CIT gene expres-
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Figure 5. Kaplan-Meier survival analysis based on categorized gene expression levels of the HOTPAM9 genes. 
(a) Kaplan-Meier survival curves based on categorized gene expression levels for all the HOTPAM9 genes 
(n = 223). Overall survival stratified based on high or low gene expression analysis for the Moffitt TCC data set. 
For all the HOTPAM9 genes the overall log rank test is significant. p value between primary groups is shown in 
each plot (left two panels). Kaplan-Meier Recurrence-Free survival (RFS) curves are based on categorized gene 
expression levels for all the HOTPAM9 genes (n = 173). For RFS in the MSKCC data set, the overall log rank 
tests are all significant (right two panels). (b) Performance of statistical stratification model built on the basis of 
gene expression data of CIT/STK21 and HSPB8 as biomarkers to distinguish indolent from aggressive disease 
in MSKCC training data set. Stratification scores for the aggressive disease were compared between patients 
with primary tumors and those with metastatic tumors (left). ROC curve analysis was used to evaluate an ability 
to distinguish patients with primary cancer from those with metastatic disease (right). (c) Performance of the 
stratification model on Moffitt TCC data set by dividing patients’ classification scores at the optimal threshold 
(left). ROC curve was used to evaluate overall performance of the stratification model (right).
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tumor-promoting role for CIT kinase has also been proposed for other cancers such as colorectal, breast, and 
cervical cancers43,49,50. While potential interacting partners and substrates of CIT kinase have been identified, 
the mechanism by which CIT/STK21 expression is regulated in cancers in general and PC in particular is not 
known51. Reduced expression of CIT is associated with defective cytokinesis51, and in our study loss of CIT or 
HOXB13 impacted cell proliferation suggesting a dependency of PC cells on HOXB13-CIT transcriptional axis 
for survival. STRING analysis revealed enrichment of mitotic kinases in the HOTPAM9 genes uncovered CIT 
kinase, not, linked to other genes. This is a hitherto uncharacterized association that we have identified through 
this study. In PC3 cells, c-MYC expression was induced following HOXB13 knockdown suggesting a functional 
redundancy in AR negative cells for regulating expression of mitotic kinases. However, AR positive cancers 
appear to rely more predominantly on HOXB13 for proliferation.
Activation of oncogenes that relay mitogenic signals and inactivation of tumor suppressors that restrain 
growth is a hallmark of many cancers. A striking observation in this study is the consistent downregulation of 
HSPB8 gene expression to a certain extent in primary but quite significantly in metastatic PCs. HSPB8, codes for 
a 22 kDa heat shock protein, has been shown to clear mutant AR protein in motoneuronal cells52. We observed 
that the gene expression of HSPB8, an atypical member of the heat shock protein family, inversely correlated with 
AR and HOXB13 mRNA expression in metastatic PCs from multiple organ sites, particularly bone metastatic 
PCs (Supplementary Fig. 9; Supporting Data Tables 11–13). Notably, treatment with AR antagonist Enzalutamide 
did not suppress HOXB13 mRNA expression and despite an increase in HSPB8 mRNA it was not sufficient to 
induce HSPB8 protein expression. In contrast, in Colchicine-treated cells, HOXB13 was not only downregulated 
but this also led to a significant restoration of HSPB8 protein levels and a significant inhibition of cell migration. 
This is consistent with recent studies that demonstrated that overexpression of HSPB8 led to cell cycle arrest and 
apoptosis in certain melanoma models29,53. It remains to be seen whether HSPB8 is the main target of Colchicine 
action and whether it can be employed to prevent metastatic progression of HOXB13 positive PCs in pre-clinical 
mouse models.
These results with Enzalutamide suggest that the androgen-bound AR may either inhibit HOXB13 from 
binding to the HSPB8 gene locus in primary tumors or it may sequester HOXB13 from a repressive effect on 
HSPB8 gene expression. A suppressive effect of HOXB13 on androgen-stimulated PSA expression by AR has 
been proposed as mechanism of regulation in a context dependent manner11,21. Androgen depletion may facilitate 
HOXB13 recruitment to the HSPB8 gene locus to suppress its expression and override the brake on cell prolifer-
ation. In corollary, a pro-proliferative role for HSPB8 has been reported in certain breast cancer models. In these 
studies, it was observed that HSPB8 protein is induced in response to estrogen stimulation of MCF7 and T47D 
(estrogen-dependent cell lines) breast cancer cells, whereas it was neither detected nor induced in the triple neg-














Age at diagnosis 
(years) <64 Years > = 64 Year 1.59 (0.69,3.65) 0.2748 0.2748





5–6 8–10 31.19 (6.83,142.36) <0.0001 19.5 (4, 95.09) 0.0002
Clinical Tumor 
Stage T1C T2,T2A,T2B,T2C 0.69 (0.29,1.63) 0.3994 0.0018
T1C T3,T3A,T3B,T3C 6 (1.96,18.43) 0.0017
Lymph node 





Margin Status Negative Positive 2.7 (1.26,5.79) 0.0106 0.0106
PSA at 
Diagnosis <10 > = 10 2.25 (0.98,5.17) 0.0557 0.0557
MKI67 Low High 2.05 (0.95,4.43) 0.0663 0.0663
NEK2 Low High 2.59 (1.16,5.78) 0.0198 0.0198
AURKA Low High 0.81 (0.37,1.74) 0.5810 0.5810





CIT Low High 1.62 (0.76,3.45) 0.2117 0.2117
HSPB8 Low High 0.5 (0.23,1.07) 0.0725 0.0725
NCAPG Low High 2.54 (1.16,5.56) 0.0198 0.0198
TRPM8 Low High 1.52 (0.69,3.32) 0.2963 0.2963
NUF2 Low High 1.59 (0.75,3.41) 0.2294 0.2294
Table 2. Univariate and Multivariable Recurrence-Free Survival Analysis for Primary Patients in MSKCC data 
set. Backwards Selection at removal alpha = 0.05.
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in G2/M54. Further, HSPB8 is linked to tamoxifen resistance in breast cancers and correlates with poor clinical 
outcome55. Collectively these results suggest a context dependent role for HSPB8 in hormone refractory cancers.
An area of future investigation is whether HOXB13 actively recruits co-repressors at the HSPB8 genomic 







































































































TCC Data  Set MSKCC Data  Set
a
Figure 6. CIT/STK21 serine-threonine kinase is a direct target of HOXB13 in prostate cancer. (a) Analysis 
of HOXB13 or AR recruitment sites in the proximity of the CIT/STK21 in normal prostate (1–7 green peaks), 
human prostate tumors (8–20, orange peaks) and FOXA1 ChIP-seq in tumor (orange peak - line 21), HOXB13 
ChIP-seq tumor (orange peak - line 22), HOXB13 ChIP-seq in LNCaP (blue peak - line 23), AR ChIP-seq in 
normal prostate cell line LHSAR transfected with HOXB13, FOXA1, HOXB13 plus FOXA1 (blue peaks- line 
24–27) (ChIP-seq data from GSE56288). (b) Directed ChIP-quantitative PCR for the recruitment of HOXB13 
to CIT/STK21 promoter with anti-HOXB13 antibodies, anti-AR antibodies or IgG (control). IGX1A is control 
site. ± SEM. ****p < 0.0001, ns: not significant. (c,d) Kaplan-Meier overall survival curves based on categorized 
gene expression levels of HOTPAM9 genes in Moffitt TCC data set and Recurrence Free Survival curves in the 
MSKCC data set. p values were generated by the log-rank test.
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silenced by methylation56. Which histone methyltransferase or DNA methyltransferase act in conjunction with 
HOXB13 to repress HSPB8 expression during metastatic progression remains to be determined. Overall, our 
study reveals HOXB13 as a master transcriptional regulator of PC metastasis and has identified actionable targets 
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HOXB13
Figure 7. HSPB8 expression is downregulated in metastatic prostate cancer. (a) Comparison of AR, HOXB13, 
and HSPB8 gene expression in bone metastatic CRPCs (GSE101607) **p < 0.005, ****p < 0.0005. (b) GSE6752 
which comprised 10 primary and 21 androgen ablation resistant metastatic samples. ****p < 0.0005. (c) 
GSE67980 (human primary and metastatic cases) ***p < 0.005; *p < 0.05. ns = not significant. (d) Moffitt TCC 
primaries. ****p < 0.0005; *** p < 0.005. (e) Moffitt TCC metastasis. ****p < 0.0005. (f) Moffitt TCC Data 
Set. ****p < 0.0005. (g) AR/HOXB13 co-expression is observed in 94 (63%) of metastatic PC cases (SU2C/PCF 
cohort, Cell 2015). HSPB8 expression inversely correlates with AR and HOXB13 expression. Pearson co-relation 
co-efficient and Spearman rank co-efficient are shown below each panel.
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Materials and Methods
Cell culture, antibodies and vectors. RWPE-1, PC3, DU145, VCaP, 22Rv1 and LNCaP were obtained 
from American Type Culture Collection (ATCC), that are authenticated by Short Tandem Repeat Profiling and 
used within 5–10 passages and replenished from stocks. C4-2B is described earlier2. All cell lines were incu-
bated in a humidified atmosphere of 5% CO2 at 37 °C and cultured as described earlier2. Cultures are routinely 

























































































































Figure 8. Overexpression of HSPB8 inhibits migration of metastatic prostate cancer cells. (a) Expression of 
HOXB13, AR and HSPB8 in various cell line models. RWPE-1 is AR-low; VCaP, LNCaP, C4-2B and 22Rv1 
are AR-positive; PC3 and DU145 are AR-negative cell lines. (b) C4-2B cells were transfected with 4 µg of 
GFP-Vector or GFP-HSPB8. Whole cell lysates were immunoblotted with anti-HSPB8 antibody. Actin is a 
normalization control. (c) Stratification of PC cell lines based on their HOXB13, AR and AR-V7 expression. 
(d,e) C4-2B, PC3 and 22Rv1 cells were transfected with 4 µg of GFP-Vector or GFP-HSPB8. Transwell cell 
migration assay was performed using fluroblock inserts. (d) After 16 h, cells were visualized and captured using 
the EVOS-M5000 microscope. Scale bar 300 µm. (e) Quantitative analysis of GFP-positive migrated cells. n = 2 
independent replicates. ± SEM. **p < 0.01.
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Figure 9. Colchicine a microtubule inhibitor induces HSPB8 protein expression and inhibits mCRPC 
migration. (a) Androgen-responsive LNCaP and androgen-independent C4-2B cells were treated with Vehicle 
(DMSO) or 5 µM of Enzalutamide. Total RNA was isolated, followed by qRT-PCR with HOXB13, c-MYC and 
HOTPAM9 primers. (b,c) C4-2B cells were transfected with control, HOXB13 or AR siRNAs, followed by 
treatment with Vehicle or Enzalutamide (5 µM) and expression of HOTPAM9 genes was determined by qRT-
PCR. (d,e) Directed ChIP-quantitative PCR for HOXB13 recruitment to sites upstream of the HSPB8 gene with 
HOXB13 antibody or IgG in LNCaP (d) and C4-2B (e) cells. Chromosomal locations (Peak1: Chr:119,614,158- 
119,614,438) and (Peak2: Chr:119,616,400- 119,616,900). Data are represented as mean ± SEM. ****p < 0.0001; 
***p < 0.001; **p = 0. 0025, *p < 0.05t. C4-2B and 22Rv1 were treated with Vehicle (DMSO), 10 µM of 
Enzalutamide (Enz) or 1 µM of Colchicine (Col) for 24 h. (f-i) Total RNA was isolated, followed by qRT-
PCR with HOXB13, HSPB8 and Actin primers. (j) Whole cell lysates were immunoblotted with anti-HSPB8, 
anti-HOXB13 and anti-AR antibody. Actin is a normalization control. (k) Transwell cell migration assay was 
performed on GFP-positive PC3 and 22Rv1 cells using fluroblock inserts. Scale bar 300 µm. n = 2 independent 
replicates. (l) Quantitation of cell migration shown in (k). Data are represented as mean ± SEM in (f-i and l). 
****p < 0.0001, ***p < 0.0005, **p < 0.01, *p < 0.05, ns: not significant.
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by PCR based screening. HOXB13 F-9 monoclonal antibody (Cat #SC-28333) was purchased from Santa Cruz 
and HOXB13 rabbit polyclonal antibodies were purchased from Genetex (GTX129245). HSPB8 (Abcam Cat# 
Ab79784), Actin antibodies (Sigma-Aldrich Cat# A2228), were purchased from Abcam. AR (F39.4.1) antibody 
was purchased from Biogenex. siRNAs were purchased from multiple sources. Source for all siRNA and sequences 
are provided in the Supporting data section. GFP-HSPB8 expression vector was synthesized and sequenced by 
Genscript. Prostate cancer cells were transfected with siRNAs or plasmids using LONZA nucleofector kit.
Gene expression profiling. Total RNA was extracted from the prostate cells (QIAGEN mRNAeasy kit, 
Germany) and analyzed as described earlier16. Primers used for qRT-PCR for detection of HOTPAM9 genes, 
HOXB13, AR, AR-V7, PSA (KLK3), NKX3.1, TMPRSS2, c-MYC and Actin, as well as primers for ChIP analysis of 
HSPB8, CIT, AURKB, NCAPG, TRPM8, NUF2  and IGX1A (control primers) are listed in Supporting data section.
RNA sequencing data analysis. Heat maps and Venn diagrams were produced with Partek (Partek, Inc.) 
and GENE-E software from Broad Institute (https://software.broadinstitute.org/GENE-E/). Analysis of overlaps 
from the lists of differentially expressed genes was performed using custom Perl scripts.
Moffitt total cancer care (TCC) data set. Moffitt Information Shared Services/Collaborative Data 
Services Core provided the de-identified gene expression data for the 194 primary and 29 metastatic tumors 
(Rosetta/Merck Human RSTA Custom Affymetrix 2.0 microarray [HuRSTA_2a520709.CDF]) from the Moffitt 
Total Cancer Care (TCC) dataset. Studies that fall under the TCC protocol have been obtained with patients’ 
written consent.
external validation data set. We downloaded GSE21034 series, (MSKCC dataset)28 and GSE691957 from 
Gene Expression Ominibus (GEO) for external validation. The MSKCC data set for bioinformatics analysis com-
prised 179 samples (29 normal, 131 primary and 19 metastatic tumors). The GSE6919 dataset comprised 504 
samples (233 normal, 196 primary and 75 metastatic tumors) The downloaded raw data were normalized using 
quantile normalization. The heat map of each gene set was generated using heatmap2 with in-house R scripts16.
Principle component analysis (PCA). Gene expression data for the HOXTAR87 genes were extracted 
from the Moffitt TCC data set as well as the MSKCC data set (Supporting data section). PCA was performed using 
the Evince software (Prediktera, ver2.7.9). We observed a separation between primary and metastatic samples in 
the second component. To identify a minimal gene set driving this separation, we extract the PCA loading values 
of each gene. We selected the genes with very highest/smallest loading values. The genes with smallest absolute 
loading values were gradually removed from the list so that the first component value is not reduced. Finally, nine 
gene sets were obtained which can separate the primary from the metastatic with the highest first component 
value of 58%.
Cell proliferation and cell migration assay. Cell number was determined by harvesting cells, staining 
with Trypan blue and counting by hemocytometer. Cell migration was performed using Fluroblock transwell cell 
migration assay.
statistical analysis. Differences in means between individual groups were analyzed by Student’s t-test, or 
analysis of variance (ANOVA). Two-sided p-values < 0.05 were considered statistically significant.
Statistical analysis for human tumor data. Descriptive analysis was conducted for all the variables 
interested (age, Gleason score, clinical tumor stage, lymph node involvement, and margin status, PSA at diagno-
sis and gene expression data for selected genes). Fisher’s exact test was used to compare distribution of clinical 

























Figure 10. A schematic showing key mitotic kinases over-expressed in metastatic PCs and regulated by 
HOXB13. HSPB8 functions as a restraint against PC metastasis.
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variables between patients with primary cancer and those with metastatic cancer. Kaplan-Meier (KM) survival 
curves were plotted with R 3.3.2. For primary cancers, univariate and multivariable Cox proportional hazard 
regression analysis were used. Variables with two-sided p-value less than 0.05 in the univariate analysis were 
included in the multivariable analysis. Backward selection allowing variable removal at the significance level of 
0.05 was used to screen significant variables. These statistical analyses were made using SAS 9.4. A multivariable 
logistic regression model was trained to predict metastatic PC patients on the basis of normalized gene expression 
of MSKCC data set. A stepwise variable selection method based on Akaike information criterion (AIC) was used 
to select the optimal logistic regression model. Receive operating characteristic (ROC) curve was used to evaluate 
overall performance of the logistic regression model in classifying primary patients from those with metastatic 
disease58. Wilcoxon rank sum test was used to compare Gleason scores of two groups. These statistical analyses 
were performed using R 3.3.2.
Data Availability
Materials, gene expression data and associated protocols will be available upon reasonable request.
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